Table 4.

The incidence of adverse events between the two groups.

	Roxadustat group (n = 28))	Control group (n = 32)	p
Hb level above target n (%)	9 (32.1)	6 (18.8)	0.232
Hypertension n (%)	4 (14.30)	11 (34.40)	0.073
Hyperkalemia n (%)	4 (14.30)	3 (9.40)	0.695
Nausea n (%)	2 (7.1)	3 (9.40)	1.000
Diarrhea n (%)	1 (3.60)	0 (0.00)	0.467
Dizziness n (%)	2 (7.1)	4 (12.5)	0.675
Abnormal liver function n (%)	0(0.00)	1(3.10)	1.000